Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : SRNE crawled time : 21:00 save search
Antibody-drug Conjugates Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain
Published: 2023-06-26 (Crawled : 21:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 2.15%
H: 1.18%
C: 0.43%
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: -1.0%
H: 4.2%
C: 1.3%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.82%
H: 0.02%
C: -0.85%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.17%
H: 0.0%
C: 0.0%
OMER | $3.08 0.0% 210K
|
Health Technology
|
| O: 0.19%
H: 2.22%
C: 1.76%
IMGN | News | $31.23 0.03% 49M
|
Health Technology
|
| O: 0.58%
H: 2.57%
C: 0.26%
companies pipeline trial
Delisting of Securities of Core Scientific, Inc.; The Very Good Food Company Inc.; HyreCar Inc.; Reeds, Inc.; Sorrento Therapeutics, Inc.; CYREN Ltd.; Lucira Health, Inc.; Qutoutiao Inc.; and Sio Gene Therapies Inc. from The Nasdaq Stock Market
Published: 2023-04-10 (Crawled : 21:00) - globenewswire.com
CYRNQ | $0.0001 0% 600
|
n/a
|
| O: -16.8%
H: 75.48%
C: 55.29%
HYREQ | $0.0002 4300.0% 120K
|
n/a
|
| O: -19.89%
H: 34.04%
C: 34.04%
SIOX | $0.478 -20.5% 40K
|
Health Technology
|
| O: 0.0%
H: 0.43%
C: 0.0%
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 0.25%
H: 2.1%
C: -3.38%
NDAQ | $61.095 -0.17% -0.17% 2.3M
|
Finance
|
| O: 0.0%
H: 0.59%
C: -0.06%
food market
Sorrento Issues Update to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)
Published: 2023-02-17 (Crawled : 21:00) - globenewswire.com
SCLX | $0.984 3.43% 3.31% 550K
|
| Email alert
Add to watchlist
SRNE | $0.015 -8.85% 140K
|
Health Technology
| Email alert
Add to watchlist
update
Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today’s Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc.
Published: 2023-02-13 (Crawled : 21:00) - globenewswire.com
SCLX | $0.984 3.43% 3.31% 550K
|
|
| O: 0.56%
H: 16.29%
C: 14.04%
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: -4.74%
H: 9.55%
C: -19.39%
Sorrento Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology (ESMO)
Published: 2022-12-05 (Crawled : 21:00) - globenewswire.com
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 1.68%
H: 0.0%
C: -7.02%
imc-001 medical positive
Sorrento Announces That Sorrento Mexico Has Sold Out of One Million COVISTIX Tests Last Week in Mexico
Published: 2022-01-19 (Crawled : 21:00) - globenewswire.com
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 0.47%
H: 5.59%
C: -2.8%
test
Sorrento Therapeutics Mexico to Partner with the World Boxing Council for the Screening of COVID-19 of all Convention Attendees with COVI-STIX at the 59th World Boxing Council Convention in Mexico City
Published: 2021-11-12 (Crawled : 21:00) - globenewswire.com
SRNE | $0.015 -8.85% 140K
|
Health Technology
| Email alert
Add to watchlist
covid
Sorrento Announces Its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 – Elicits Strong Neutralizing Immune Responses in Vaccinated Animals Against SARS-CoV-2 and Multiple Major Variants of Concern
Published: 2021-08-19 (Crawled : 21:00) - globenewswire.com
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 0.36%
H: 3.02%
C: 0.85%
DYAI 4 | $1.5 -1.96% -2.0% 8.8K
|
Health Technology
|
| O: -1.33%
H: 8.99%
C: 6.07%
covid animals vaccine sars-cov-2
Sorrento Receives Authorization From the UK Regulatory Agency to Conduct a Phase 2 Clinical Trial for COVI-DROPS in an Outpatient Setting
Published: 2021-06-11 (Crawled : 21:00) - globenewswire.com
SRNE | $0.015 -8.85% 140K
|
Health Technology
| Email alert
Add to watchlist
phase 2 drop trial authorized
Sorrento Announces Updated Positive Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients
Published: 2021-03-25 (Crawled : 21:00) - biospace.com/
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: -3.55%
H: 7.49%
C: 5.9%
covid treatment positive results phase 1 positive results phase 1b phase 2b
Sorrento Announces Subsidiary Company - ADNAB, Inc. - to Develop and Commercialize ADNAB™ Platform Products for Hematological Malignancies and Solid Tumors Based on an Exclusive Technology License From the Mayo Clinic
Published: 2021-02-08 (Crawled : 21:00) - globenewswire.com
SRNE | $0.015 -8.85% 140K
|
Health Technology
|
| O: 0.73%
H: 3.43%
C: -3.07%
license commercialization solid tumors
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.